AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8504712 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estrogen vs. calcium
Number of subjects: 38
Study 3673928 — intervention group
Group type: EXPERIMENTAL
Intervention: 65 mg/d AA intake for 2 weeks
Number of subjects: 11
Study 3673928 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/d AA intake for 4 weeks
Number of subjects: 11
Study 3673928 — intervention group
Group type: EXPERIMENTAL
Intervention: 605 mg/d AA intake for 3 weeks
Number of subjects: 11
Study 3673928 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/d AA intake for 4 days
Number of subjects: 11
Study 3673928 — intervention group
Group type: EXPERIMENTAL
Intervention: 605 mg/d AA intake for 4 days
Number of subjects: 11
Study 3673928 — intervention group
Group type: EXPERIMENTAL
Intervention: 65 mg/d AA intake for 3 days
Number of subjects: 11
Study 3673928 — intervention group
Group type: EXPERIMENTAL
Intervention: AA intake calculated to maintain plasma AA levels of at least 0.4 mg/dL (23 mumol/L)
Number of subjects: 11
Study 3673928 — intervention group
Group type: EXPERIMENTAL
Intervention: Average AA intake estimated to maximize total body pool
Number of subjects: 11
Study 3673928 — intervention group
Group type: COMPARATOR
Intervention: Urinary AA levels
Number of subjects: 11
Study 3673928 — intervention group
Group type: COMPARATOR
Intervention: Salivary AA levels
Number of subjects: 11
Study 29300728 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment (IIT)
Number of subjects: 10
Study 29300728 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 10
Study 27002277 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 326
Study 27002277 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 326
Study 23828313 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nasal anesthetic (TNA)
Number of subjects: 0
Study 23828313 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 0
Study 23116451 — intervention group
Group type: EXPERIMENTAL
Intervention: Settled swine facility organic dust extract (ODE)
Number of subjects: 0
Study 23116451 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptidoglycan (PGN)
Number of subjects: 0
Study 23116451 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS)
Number of subjects: 0
Study 23116451 — intervention group
Group type: COMPARATOR
Intervention: Modified whole blood assay (WBA)
Number of subjects: 0
Study 23116451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum inflammatory markers (TNF‐α, IL‐8, IL‐6, IL‐10)
Number of subjects: 0
Study 20855984 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 7
Study 20855984 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine
Number of subjects: 7
Study 18641546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose mycophenolate mofetil (MMF)
Number of subjects: 332
Study 18641546 — intervention group
Group type: COMPARATOR
Intervention: Concentration-controlled MMF therapy
Number of subjects: 332
Study 18641546 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus treatment
Number of subjects: 332
Study 18641546 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine treatment
Number of subjects: 332
Study 18641546 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diarrhea
Number of subjects: 332
Study 18641546 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without diarrhea
Number of subjects: 332
Study 18641546 — intervention group
Group type: EXPERIMENTAL
Intervention: -840G>A UGT2B7 SNP
Number of subjects: 332
Study 15914521 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (50% reduction overweight by caloric restriction)
Number of subjects: 11
Study 12629233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-modal stimuli (visual and tactile)
Number of subjects: 18
Study 12629233 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimodal stimuli (tactile or visual)
Number of subjects: 18
Study 10334216 — intervention group
Group type: EXPERIMENTAL
Intervention: Glottic reconstruction with false vocal fold (FVF) mucosal flap
Number of subjects: 27
Study 10334216 — intervention group
Group type: COMPARATOR
Intervention: Standard frontolateral partial laryngectomy (FLPL) without glottic reconstruction
Number of subjects: 27
Study 7489171 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 299
Study 7489171 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomy cholecystectomy
Number of subjects: 299
Study 1850946 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam, 5 mg
Number of subjects: 95
Study 1850946 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam, 10 mg
Number of subjects: 95
Study 1850946 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam, 15 mg
Number of subjects: 95
Study 1850946 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 95
Study 6786536 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of folic acid a day before and during early pregnancy
Number of subjects: 60
Study 6786536 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study 31415123 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term low-dose clarithromycin (CAM) therapy
Number of subjects: 28
Study 31415123 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clarithromycin therapy)
Number of subjects: 28
Study 29334438 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized 0.454% stannous fluoride dentifrice with zinc citrate
Number of subjects: 80
Study 29334438 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride dentifrice
Number of subjects: 80
Study 29334438 — intervention group
Group type: COMPARATOR
Intervention: Negative control fluoride dentifrice
Number of subjects: 80
Study 26073493 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide (90 mg every 4 weeks) for 6 months
Number of subjects: 59
Study 23147275 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating Heart Problems programme (8-week group programme based on cognitive behaviour therapy and motivational interviewing)
Number of subjects: 275
Study 23147275 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 275
Study 22703478 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (12.5 mg)
Number of subjects: 57
Study 22703478 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg)
Number of subjects: 57
Study 19938654 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing about emotionally dissonant experiences for three weeks
Number of subjects: 20
Study 19938654 — intervention group
Group type: COMPARATOR
Intervention: Control condition (without writing)
Number of subjects: 20
Study 17336229 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg intravenously three times daily for 5 days)
Number of subjects: 19
Study 17336229 — intervention group
Group type: COMPARATOR
Intervention: Control (saline administered in equal volume)
Number of subjects: 19
Study 15111377 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (4 mg/patch) twice weekly for 6 months
Number of subjects: 57
Study 15111377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 11930721 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Chip (CHX) following scaling and root planing (SRP)
Number of subjects: 65
Study 11930721 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 65
Study 9559377 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive estimation of left ventricular stroke volume including zero velocity flow
Number of subjects: 40
Study 9559377 — intervention group
Group type: COMPARATOR
Intervention: Doppler stroke distance
Number of subjects: 40
Study 9559377 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler stroke distance and long axis motion
Number of subjects: 40
Study 7942720 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional bowel disorder (FBD) in women with dysmenorrhea (DYS)
Number of subjects: 383
Study 7942720 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without dysmenorrhea)
Number of subjects: 383
Study 7942720 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroticism scores
Number of subjects: 383
Study 7942720 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel symptoms
Number of subjects: 383
Study 7942720 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful menses and water retention
Number of subjects: 383
Study 7942720 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin levels
Number of subjects: 383
Study 3221029 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 31
Study 3221029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 2184564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin alone, modified MVAC scheme, or combination of cisplatin and methotrexate (3 cycles)
Number of subjects: 52
Study 22216504 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (120 mg daily)
Number of subjects: 14
Study 22216504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31673858 — intervention group
Group type: EXPERIMENTAL
Intervention: Twisted File Adaptive (TFA) system (n = 35)
Number of subjects: 64
Study 31673858 — intervention group
Group type: COMPARATOR
Intervention: Reciproc system (n = 29)
Number of subjects: 64
Study 30658699 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment escalation (initial prednisone and methotrexate, changed every 4 months)
Number of subjects: 381
Study 30658699 — intervention group
Group type: COMPARATOR
Intervention: Treatment tapering (tapering MTX)
Number of subjects: 381
Study 30658699 — intervention group
Group type: COMPARATOR
Intervention: No treatment (no DFR)
Number of subjects: 381
Study 30658699 — intervention group
Group type: COMPARATOR
Intervention: Drug-free remission (DFR)
Number of subjects: 381
Study 28298021 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nimodipine (1-2 mg/hour) and hydroxyethyl starch (HES) from the day before surgery until the 7th postoperative day
Number of subjects: 182
Study 28298021 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nimodipine and HES
Number of subjects: 182
Study 28298021 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 182
Study 25498787 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation (writing about a core personal value)
Number of subjects: 0
Study 25498787 — intervention group
Group type: COMPARATOR
Intervention: Insulting evaluative feedback
Number of subjects: 0
Study 25498787 — intervention group
Group type: COMPARATOR
Intervention: Neutral evaluative feedback
Number of subjects: 0
Study 23343649 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous tranexamic acid (TA) dosing: 10 mg/kg followed by an infusion of 1 mg·kg·h(‐1) throughout the operation, and 10 mg/kg into the CPB.
Number of subjects: 21
Study 23343649 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous tranexamic acid (TA) dosing: 10 mg/kg, then 10 mg/kg into the CPB and 10 mg·kg·h(‐1) at the end of CPB.
Number of subjects: 21
Study 21112921 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle modification (TLM) program for 4 weeks
Number of subjects: 29
Study 21112921 — intervention group
Group type: COMPARATOR
Intervention: Control group maintaining usual lifestyle behavior
Number of subjects: 29
Study 19242355 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin
Number of subjects: 36
Study 19242355 — intervention group
Group type: COMPARATOR
Intervention: 5 mg atorvastatin
Number of subjects: 36
Study 17381945 — intervention group
Group type: EXPERIMENTAL
Intervention: Western advertising and media exposure
Number of subjects: 800
Study 17381945 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 800
Study 17381945 — intervention group
Group type: EXPERIMENTAL
Intervention: General eating styles
Number of subjects: 800
Study 17381945 — intervention group
Group type: EXPERIMENTAL
Intervention: Body esteem levels
Number of subjects: 800
Study 15281543 — intervention group
Group type: EXPERIMENTAL
Intervention: CobraPLA
Number of subjects: 81
Study 15281543 — intervention group
Group type: COMPARATOR
Intervention: LMA
Number of subjects: 81
Study 11583768 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9156415 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 50
Study 9156415 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMW heparin)
Number of subjects: 50
Study 7961015 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole abdominal irradiation using a four orthogonal field's technique (30 grays, 1.5 Gy/fraction/day, 20 fractions over 30 days)
Number of subjects: 167
Study 7961015 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole abdominal irradiation with a four orthogonal field's technique
Number of subjects: 167
Study 3651280 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2.5 micrograms kg‐1 i.v.
Number of subjects: 30
Study 3651280 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 7.5 micrograms kg‐1 i.v.
Number of subjects: 30
Study 3651280 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 30042471 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling (four sessions)
Number of subjects: 492
Study 28262529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous neostigmine 2.5mg
Number of subjects: 90
Study 28262529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide 20mg
Number of subjects: 90
Study 28262529 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of neostigmine and metoclopramide
Number of subjects: 90
Study 28262529 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 90
Study 28262529 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 90
Study 28262529 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 90
Study 25252602 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy followed by surgery (Arm B)
Number of subjects: 66
Study 25252602 — intervention group
Group type: COMPARATOR
Intervention: Primary surgery (Arm A)
Number of subjects: 66
Study 25252602 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy followed by surgery (Arm B) after tumor resection
Number of subjects: 66
Study 25252602 — intervention group
Group type: COMPARATOR
Intervention: Primary surgery (Arm A) after tumor resection
Number of subjects: 66
Study 24180552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice (4 oz)
Number of subjects: 20
Study 24180552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice (8 oz)
Number of subjects: 20
Study 24180552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice (12 oz)
Number of subjects: 20
Study 24180552 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tomato juice)
Number of subjects: 20
Study 21223267 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-event connections that were positive and about stable aspects of the self
Number of subjects: 130
Study 21223267 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared self-event connections
Number of subjects: 130
Study 18688808 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (opiate blocker) administered in a double-blind, crossover design for 7 weeks with an additional 14 hr/week of observation
Number of subjects: 36
Study 18688808 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher morning levels of B-endorphin relative to ACTH
Number of subjects: 36
Study 17044955 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted spoons with thickened handles (diameters of 1, 3, and 5cm) filled with water
Number of subjects: 10
Study 17044955 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted spoons with thickened handles (diameters of 1, 3, and 5cm) filled with sugar
Number of subjects: 10
Study 17044955 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 healthy comparison participants; 4 males, 8 females; mean age 25y 6mo [SD 3y 0mo]; range 20y 0mo‐30y 0mo)
Number of subjects: 10
Study 12551734 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavandula tincture (1:5 in 50% alcohol) 60 drops/day plus placebo tablet (Group A)
Number of subjects: 45
Study 12551734 — intervention group
Group type: COMPARATOR
Intervention: Imipramine 100 mg/day plus placebo drop (Group B)
Number of subjects: 45
Study 12551734 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 100 mg/day plus lavandula tincture 60 drops/day (Group C)
Number of subjects: 45
Study 10546926 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg filgrastim
Number of subjects: 24
Study 10546926 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg filgrastim
Number of subjects: 24
Study 10546926 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg filgrastim
Number of subjects: 24
Study 10546926 — intervention group
Group type: EXPERIMENTAL
Intervention: filgrastim (all doses)
Number of subjects: 24
Study 10546926 — intervention group
Group type: EXPERIMENTAL
Intervention: filgrastim
Number of subjects: 24
Study 10546926 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 8934063 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms EE + 75 micrograms gestodene
Number of subjects: 58
Study 8934063 — intervention group
Group type: COMPARATOR
Intervention: 30 micrograms EE + 75 micrograms gestodene
Number of subjects: 58
Study 1991883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride 11.7%
Number of subjects: 600
Study 1991883 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing concentrations of hypertonic saline
Number of subjects: 600
Study 6838746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative methadone 10 mg i.v. at induction of anaesthesia
Number of subjects: 0
Study 6838746 — intervention group
Group type: COMPARATOR
Intervention: Postoperative methadone 10 mg i.v. following operation
Number of subjects: 0
Study 28516874 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 290
Study 28516874 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 290
Study 28516874 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 290
Study 27734219 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg plus caffeine 65 mg (test)
Number of subjects: 26
Study 27734219 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 650 mg (reference)
Number of subjects: 26
Study 25156114 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected patients on HAART
Number of subjects: 574
Study 25156114 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV patients not on HAART (non-HAART)
Number of subjects: 574
Study 25156114 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected patients (HIV(-)TB(+))
Number of subjects: 574
Study 22505700 — intervention group
Group type: EXPERIMENTAL
Intervention: Double filtration plasmapheresis (DFPP) in combination with leflunomide and methotrexate (MTX)
Number of subjects: 60
Study 22505700 — intervention group
Group type: COMPARATOR
Intervention: Leflunomide plus methotrexate (no-DFPP group)
Number of subjects: 60
Study 21102997 — intervention group
Group type: COMPARATOR
Intervention: Doxepin 3 mg
Number of subjects: 240
Study 21102997 — intervention group
Group type: COMPARATOR
Intervention: Doxepin 1 mg
Number of subjects: 240
Study 21102997 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin 1 mg and 3 mg
Number of subjects: 240
Study 18202421 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Control Rate (DCR) at week 8
Number of subjects: 984
Study 18202421 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Response (CR) or Partial Response (PR) at week 8
Number of subjects: 984
Study 18202421 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Control Rate (DCR)
Number of subjects: 984
Study 18202421 — intervention group
Group type: EXPERIMENTAL
Intervention: Median survival times
Number of subjects: 984
Study 18202421 — intervention group
Group type: EXPERIMENTAL
Intervention: Median time to response, time to progression, and survival time
Number of subjects: 984
Study 15941876 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-fat, moderate-carbohydrate diet
Number of subjects: 40
Study 15941876 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate hypoenergetic diet (‐600 kcal/d)
Number of subjects: 40
Study 12641399 — intervention group
Group type: EXPERIMENTAL
Intervention: SP monotherapy
Number of subjects: 448
Study 12641399 — intervention group
Group type: EXPERIMENTAL
Intervention: SP/CQ combination therapy
Number of subjects: 448
Study 12641399 — intervention group
Group type: EXPERIMENTAL
Intervention: SP/AQ combination therapy
Number of subjects: 448
Study 10462143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine (CNP) 10 mg/day
Number of subjects: 35
Study 7607610 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone administration
Number of subjects: 0
Study 7607610 — intervention group
Group type: COMPARATOR
Intervention: Normal population (baseline comparison)
Number of subjects: 0
Study 2088249 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg orally, 8 hourly)
Number of subjects: 80
Study 2088249 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo tablet thrice daily)
Number of subjects: 80
Study 41544 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg at night
Number of subjects: 55
Study 41544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31751687 — intervention group
Group type: EXPERIMENTAL
Intervention: Inonotus obliquus polysaccharides (IOP) at a dosage of 50 mg/kg
Number of subjects: 0
Study 31751687 — intervention group
Group type: COMPARATOR
Intervention: Compound C (chemical inhibitor of AMPK)
Number of subjects: 0
Study 31374046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethosuximide for 2 weeks
Number of subjects: 40
Study 31374046 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 40